Clinical trials
Phase 2 Idiopathic Pulmonary Fibrosis trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
81 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2001 | 2 |
| 2002 | 1 |
| 2003 | 2 |
| 2004 | 1 |
| 2005 | 1 |
| 2007 | 1 |
| 2008 | 3 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 4 |
| 2012 | 4 |
| 2013 | 4 |
| 2014 | 1 |
| 2015 | 3 |
| 2016 | 4 |
| 2017 | 2 |
| 2018 | 3 |
| 2019 | 2 |
| 2020 | 6 |
| 2022 | 8 |
| 2023 | 5 |
| 2024 | 7 |
| 2025 | 7 |
| 2026 | 7 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 43 |
| Terminated | 17 |
| Recruiting | 11 |
| Active, not recruiting | 7 |
| Withdrawn | 2 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Boehringer Ingelheim | 5 |
| Novartis Pharmaceuticals | 4 |
| Pliant Therapeutics, Inc. | 4 |
| Biogen | 3 |
| University of Alabama at Birmingham | 3 |
| Actelion | 2 |
| Bristol-Myers Squibb | 2 |
| Celgene | 2 |
| Duke University | 2 |
| Genentech, Inc. | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Idiopathic Pulmonary Fibrosis | 81 |
| Pulmonary Fibrosis | 21 |
| Lung Diseases, Interstitial | 11 |
| Fibrosis | 9 |
| Idiopathic Interstitial Pneumonias | 6 |
| Lung Diseases | 6 |
| Hypertension, Pulmonary | 5 |
| Pulmonary Arterial Hypertension | 4 |
| Respiratory Tract Diseases | 4 |
| Hypoxia | 2 |
Trials
Showing 1 to 25 of 81. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.